Ocular Therapeutix
OCUL
73 hedge funds and large institutions have $149M invested in Ocular Therapeutix in 2018 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 23 increasing their positions, 15 reducing their positions, and 9 closing their positions.
79% more call options, than puts
Call options by funds: $1.41M | Put options by funds: $787K
56% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 9
53% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 15
7% more funds holding
Funds holding: 68 → 73 (+5)
1% more capital invested
Capital invested by funds: $147M → $149M (+$1.93M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
2.45% less ownership
Funds ownership: 58.55% → 56.1% (-2.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Man Group
London,
United Kingdom
|
+$3.16M |
| 2 |
BlackRock
New York
|
+$2.05M |
| 3 |
Millennium Management
New York
|
+$1.01M |
| 4 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$1M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$579K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.89M |
| 2 |
SHI
SV Health Investors
Boston,
Massachusetts
|
-$3.28M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.95M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$250K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$226K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MIM
76
MetLife Investment Management
Whippany,
New Jersey
| – | -$117K | -17,358 | Closed |
|
77
Jane Street
New York
| – | -$91K | -13,489 | Closed |
|
|
MLICM
78
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$82.7K | -12,259 | Closed |
|
79
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$10K | -1,500 | Closed |
|
|
LTFS
80
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | -$7K | -1,100 | Closed |
|
81
CIBC Private Wealth Group
Atlanta,
Georgia
| – | -$7K | -1,000 | Closed |
|
|
PIA
82
Piedmont Investment Advisors
Durham,
North Carolina
| – | -$4K | -560 | Closed |
|
OCUL Hedge Fund Activity: Q3 2018 in Review
73 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q3 2018, worth a combined $149M — up 1.3% from $147M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new OCUL positions and 9 closed out — a net gain of 5 holders — while 23 added to existing stakes and 15 trimmed.
The largest buyer was Man Group, opening a new position worth an estimated $3.16M. The largest seller was Fidelity Investments, cutting an estimated $5.89M.
- 73 institutional investors held Ocular Therapeutix (OCUL) as of Q3 2018, up from 68 in Q2 2018.
- Funds reported $149M of Ocular Therapeutix stock for Q3 2018, up 1.3% quarter-over-quarter.
- 14 funds opened new Ocular Therapeutix positions in Q3 2018 and 9 closed out, a net change of +5 holders.
- The largest Ocular Therapeutix buyer in Q3 2018 was Man Group, an estimated $3.16M added.
- The largest Ocular Therapeutix seller in Q3 2018 was Fidelity Investments, an estimated $5.89M sold.
Based on aggregated 13F filings for Q3 2018.